Coya Therapeutics: Treg Therapy COYA 302 on Track for ALS Approval and $2.2 Billion Revenue Potential

Current Milestones and Corporate Developments Coya Therapeutics (COYA) has made significant operational progress in 2026, making the company increasingly attractive to investors. At the center of the recent developments is the leading product candidate COYA 302, which received the coveted Fast Track designation from the US FDA in May 2026 for the treatment of Amyotrophic Lateral Sclerosis (ALS). This status allows for expedited review and closer collaboration with regulators, underlining the high medical need in this area. Additionally, the ongoing...